FDA approves new treatment for certain stage III colon cancer
The FDA approved atezolizumab for adjuvant treatment of stage III mismatch repair-deficient colon cancer. The approval is based on findings from a clinical trial involving patients aged two and older.
Why it matters
This affects patients with a specific type of colon cancer. The evidence comes from a clinical trial.
Approval details
The drug was approved in combination with a fluoropyrimidine and oxaliplatin for use in adjuvant treatment.
Common questions
What is the approved treatment used for?
It is used for the adjuvant treatment of stage III mismatch repair-deficient colon cancer.
Who is eligible for this treatment?
Patients with stage III mismatch repair-deficient colon cancer who are two years of age or older.
Sources
- FDA Approves Adjuvant Atezolizumab for Certain Colon Cancers MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
